

# Marie D Ralff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8192618/publications.pdf>

Version: 2024-02-01

13  
papers

414  
citations

933447

10  
h-index

1125743

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

596  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Dopamine Receptors in the Anticancer Activity of ONC201. <i>Neoplasia</i> , 2018, 20, 80-91.	5.3	96
2	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. <i>Cell Cycle</i> , 2017, 16, 1790-1799.	2.6	53
3	Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. <i>Journal of Clinical Investigation</i> , 2018, 128, 2325-2338.	8.2	52
4	ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1290-1298.	4.1	40
5	Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. <i>Oncotarget</i> , 2017, 8, 81776-81793.	1.8	34
6	ONC201: a new treatment option being tested clinically for recurrent glioblastoma. <i>Translational Cancer Research</i> , 2017, 6, S1239-S1243.	1.0	31
7	Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. <i>PLoS ONE</i> , 2017, 12, e0180541.	2.5	28
8	TRAIL pathway targeting therapeutics. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 197-204.	0.7	24
9	ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 754-766.	3.4	21
10	TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. <i>Oncotarget</i> , 2020, 11, 3753-3769.	1.8	18
11	Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo. <i>Cancer Biology and Therapy</i> , 2021, 22, 607-618.	3.4	10
12	Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo. <i>Cancer Biology and Therapy</i> , 2021, , 1-10.	3.4	6
13	miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.. <i>American Journal of Cancer Research</i> , 2022, 12, 315-326.	1.4	0